WHAT IS CLAIMED IS:

1. A topical composition comprising the following ingredients:

(a) a compound having the formula:



(2)

said compound having the R stereoisomeric configuration at the 2 position and the R, S or RS stereoisomeric configuration at the 1' and 3' positions, or being a mixture thereof;

(b) anhydrous ethanol, present in an amount of at least 70 % w/w or w/v of the composition;

(c) optionally, at least one gelling or viscosity-controlling ingredient; and

(d) one or more additional carriers or excipients, one of which is isopropyl myristate or C_{12}-C_{15} alkyl lactate**;**

provided that said topical composition is anhydrous and comprises from 1% to 25 % w/w or w/v of the compound of formula (2), said composition having greater storage stability compared to a composition comprising an aqueous solvent or aqueous buffer, said ingredients being present in amounts such that the product of any transesterification is the same as the compound of formula (2).

2. The composition of claim 1, comprising from 70% to 85% w/w or w/v anhydrous ethanol.

3. The composition of claim 1 or 2, wherein at least one gelling or viscosity-controlling ingredient is present.

4. The composition of any one of claims 1-3, wherein the compound of formula (2) is selected from the group consisting of:

(ii) (2R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;

(iii) (2R,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;

(iv) (2R,3'S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;

(v) (2R,1'R,3'S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;

(vi) (2R,1'S,3'S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide;

(vii) (2R,1'R,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; and

(viii) (2R,1'S,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide.

5. The composition of any one of claims 1-4, wherein the compound of formula (2) is at a concentration of from 1% w/v or w/w to 20% w/v or w/w of the composition.

6. The composition of claim 5, wherein the compound of formula (2) is at a concentration of from 2% w/v or w/w to 10% w/v or w/w.

7. The composition of any one of claims 1-6, packaged into a multiple dose container that meters a dose of from 0.5 ml to 1.0 ml of the composition for each application.

8. The composition of any one of claims 1-6, packaged into a single or unit dose container that delivers a single or unit dose of 0.5 ml to 1.0 ml of the composition for each application.

9. The composition of any one of claims 1-8, wherein the compound of formula (2) is (2R, 3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide.

10. The composition of any one of claims 3-9, wherein the gelling or viscosity-controlling ingredient is hydroxypropyl cellulose.

11. The composition of any one of claims 3-10, further comprising citric acid.

12. The composition of any one of claims 3-11, further comprising hexylene glycol.

13. The composition of any one of claims 3-12, further comprising at least one member selected from the group consisting of dimethicone and-cyclomethicone.

14. The composition of claim 13, wherein the cyclomethicone is cyclomethicone 5-NF and/or wherein the dimethicone is dimethicone 350 c5t.

15. The composition of any one of claims 1-14, wherein isopropyl myristate is present.

16. A composition as claimed in any one of claims 1-15 for use in the treatment of hyperhidrosis wherein said composition is to be topically administered to skin of an area of a subject suffering from hyperhidrosis, before bedtime, such that, compared to untreated, baseline conditions, sweat production is reduced by at least 25% for at least six (6) hours; and such that sweat production is reduced by an amount substantially equivalent to an amount that sweat production is reduced as compared to untreated, baseline conditions, following administration of a composition comprising the same concentration of glycopyrrolate, and with an improved safety profile compared to topical glycopyrrolate.

17. A composition as claimed in any one of claim 1-15 for use in the treatment of hyperhidrosis wherein said composition is to be administered to skin of an area of a subject suffering from hyperhidrosis, such that, compared to untreated, baseline conditions, sweat production is reduced by at least 25% for at least six (6) hours; and such that sweat production is reduced by an amount substantially equivalent to an amount that sweat production is reduced as compared to untreated, baseline conditions, following administration of a composition comprising the same concentration of glycopyrrolate, and with an improved safety profile compared to topical glycopyrrolate.

18. The composition of any one of claims 1-15, for use in the treatment of hyperhidrosis, wherein said composition is to be topically administered in a one to four times daily regimen to an affected skin area of a subject.

19. The composition for use according to claim 18, wherein said composition is to be topically administered to an affected skin area of the subject, within 1-2 hours prior to the subject's sleep period.